
               
               
               7 DRUG INTERACTIONS
               
               
                  
                     
                        
                           
                              •
                              Moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin, verapamil):  Increased naloxegol concentrations; avoid concomitant use; if unavoidable, reduce dosage to 12.5 mg once daily and monitor for adverse reactions (2.4, 7.1)
                           
                           
                              •
                              Strong CYP3A4 inducers (e.g., rifampin):  Decreased concentrations of naloxegol; concomitant use is not recommended (7.1)
                           
                           
                              •
                              Other opioid antagonists:  Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use (7.1)
                           
                        
                     
                  
               
               
                  
                     
                     
                     7.1 Effects of Other Drugs on MOVANTIK 
                     
                        Table 2 displays the effects of other drugs on MOVANTIK.
                        


